AmVac has developed two biotherapeutic drugs already close to market approval which have the potential to become the new gold-standard technology in their indications. The award is given to AmVac for its outstanding works focused on the development of these biotherapeutic vaccines and treatment procedures. In presenting this award, Frost & Sullivan commends the company's proactive efforts in leveraging its knowledge in revolutionary drug discovery to resolve major bottlenecks in drug research and clinical application.
In the future, the arrival of new vaccines will result in operating margins that are at least on par with the pharma sector. The vaccines market is expected to demonstrate a CAGR of 13 per cent between 2006 and 2010. Rapid growth is anticipated in the vaccine therapeutics segment and accordingly, AmVac is poised for strong growth especially in combination with their unique indications focused on.
"AmVac has developed a portfolio of advanced products, which focus on safe and efficient applications in Urology and Gynecology," notes Frost & Sullivan Drug Discovery Technologies Programme Leader, Dr. Amarpreet Dhiman. "It focuses on those applications, where safety is particularly important, such as identifying infectious diseases that cover unmet therapeutic needs in the life sciences market."
Melinda Karpati, CEO of AmVac claims: "Over the last year, we and our partners were able to advance two innovative treatment regimens with our products while maintaining a lean but effective research and development process. Therefore we are very proud that our efforts are recognized and honoured by experts with this unique award."
The company's two principal instrument platforms Femivac® and Prostavac® have been developed and tested through collaborations with biotechnology companies and academic institutions. Femivac®, the immune-therapeutic vaccine for the treatment of Bacterial Vaginosis and Trichomoniasis has shown convincing efficacy and safety profiles with sustained protectiveness and higher effectiveness compared to commonly used drugs.
Prostavac® is the world's first patented immune-therapeutic vaccine for the treatment of Benign Prostatic Hyperplasia (BPH) and acute/chronic Prostatitis. It has shown a high success rate with 75 per cent of patients showing sustainable improvements, with marginal side effects and no surgery. Due to these factors, it has the potential to become an industry standard.
"In integrating both novel effective therapeutics and sustainable and safe medicine, thereby ushering in unmatched productivity with robustness, AmVac has been brought to the forefront of the industry," remarks Dr. Dhiman. "The company has varied application capabilities that can bring safer drugs to the market with a faster turn-around time and target different disease indications in the future."
Collaborating with several external partners, AmVac's proprietary technology has received heightened appreciation in many applications, including life research reachable and academia, fulfilling current biomarker expedition and bestowing more strategically designed screening abilities.
The Frost & Sullivan Enabling Technology of the Year Award is presented to a company that has developed a technology that can benefit or revolutionise the industry. The Award recipient has developed, through its research partners, a system that enables the development of new therapies for the treatment of crucial diseases in the human reproductive system. This breakthrough allows clinical researchers to develop procedures that allow advantages for health staff and patients on an unprecedented scale.
Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.
AmVac is a biopharmaceutical company located in Zug/Swiss. The goal of the company is the development and distribution of innovative drugs in the therapeutic indications urology and gynaecology. In these indications exists a high unmet medical need. AmVac's specific expertise is the identification of innovative drugs and therapies. These will be in licensed and brought to market through focussed clinical development studies and approval expertise. AmVac has built already a balanced portfolio with advanced products. The early pipeline is further completed through an effective network with dedicated collaboration partners in leading research groups and biotech companies.
Ms. Beatrice Roth, AMVAC AG